Characterization of ligand binding to Dopamine D3 receptor using fluorescence anisotropy and radioligand binding by Thoondee, Lakshmi
UNIVERSITY OF TARTU 
Faculty of Science and Technology 
Institute of Technology 
Lakshmi Thoondee 
Characterization of ligand binding to Dopamine D3 receptor using 
fluorescence anisotropy and radioligand binding  
Master’s Thesis (30 ECTS) 
Curriculum Bioengineering 
 
Supervisors: Maris Johanna Tahk, MSc 
Tõnis Laasfeld, MSc 






Characterization of ligand binding to Dopamine D3 receptor using fluo-
rescence anisotropy and radioligand binding  
Abstract: 
There are five subtypes of dopamine receptors that play a role in the dopaminergic system. 
Due to their limited distribution and involvement in cognitive and emotional functions, 
Dopamine D3 receptors are attractive pharmacological targets for treatment of drug addiction 
and neuropsychiatric disorders. D3 receptor ligands have been labelled with a fluorescent 
dye or a radioisotope for direct monitoring of ligand binding to the receptor. However, there 
are not many fluorescent ligands that are available for studying D3 receptor. A2-TAMRA is 
a novel fluorescent ligand with high affinity for D3 receptor. Binding of [
3H]-
methylspiperone to D3R was studied in parallel to validate results from A2-TAMRA binding 
to D3R. The D3 receptor ligands had similar affinities in inhibiting A2-TAMRA and [
3H]-
methyl spiperone binding to D3 receptor, since a very good correlation (R
2 = 0.94) was 
obtained between both methods. The affinities for the known antagonists had a good 
correlation with previously published data. Selectivity of A2-TAMRA towards two different 
subtypes was also studied and we found that A2-TAMRA prefers D3 receptor over D1 
receptor.  
Keywords: dopamine receptors, fluorescent ligand, fluorescence anisotropy assay, radi-
oligand binding assay 
CERCS: B740, P310 
Ligandi seondumine dopamiin D3 retseptoriga ja selle iseloomustus kasutades 
fluorestsentsanisotroopiat ja radioligandi seondumise meetodeid 
Dopamiiniretseptorid on G-valguga seotud retseptorid, mis vahendavad oma toimet viie 
alamtüübi - D1, D2, D3, D4 ja D5 - retseptorite kaudu. Arvestades, et D3 retseptoritel on 
piiratud ekspressioon ja osalus kognitiivsetes ja emotsionaalsetes funktsioonides. Seetõttu 
on nad farmakoloogilised sihtmärgid narkomaania ja neuropsühhiaatriliste häirete raviks. Et 
jälgida ligandi seondumist retseptoriga on D3 retseptori ligandeid märgistatud 
fluorestsentsvärvi või radioisotoopiga. A2-TAMRA on uus fluorestsentsligand, millel on 
kõrge afiinsus D3 retseptorile. A2-TAMRA on D3 retseptori suhtes selektiivsem kui D1 
retseptori suhtes. Antagonistide mõõdetud pKi oli heas vastavuses kirjandusega (R2 = 0.88), 
kuid agonistide puhul erinevus mõõdetud pKi ja kirjanduse pKi vahel oli suurem. 
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Fluorestsentsanisotroopiat tulemusi võrreldi radioligandi seondumise meetodist tulemustega 
ning kahe meetodi vahel saadi tugev korrelatsioon (R2 = 0.94).  
Võtmesõnad: dopamiin, retseptorid, fluorestsentne ligand, fluorestsentsi anisotroopia 
katse, radioligandi seondumiskatse 




TABLE OF CONTENTS 
TERMS, ABBREVIATIONS AND NOTATIONS ............................................................ 6 
INTRODUCTION ............................................................................................................. 8 
1 LITERATURE REVIEW .......................................................................................... 9 
1.1 G protein - coupled receptor structure and classification ...................................... 9 
1.1.1 GPCR signalling through G proteins .......................................................... 10 
1.1.2 GPCR desensitization and internalization ........................................................ 10 
1.2 The dopaminergic system .................................................................................. 11 
1.2.1 Dopamine receptors ................................................................................... 12 
1.2.2 D3R ligands ................................................................................................ 14 
1.3 Receptor ligand binding assays .......................................................................... 15 
1.3.1 Kinetic aspects of receptor-ligand binding assays ....................................... 16 
1.3.2 Radioligand binding assay .......................................................................... 17 
1.3.3 Fluorescence anisotropy assay .................................................................... 18 
1.4 Sf9/Baculovirus expression system.................................................................... 21 
2 THE AIMS OF THE THESIS .................................................................................. 23 
3 EXPERIMENTAL PART ........................................................................................ 24 
3.1 MATERIALS AND METHODS ....................................................................... 24 
3.1.1 MATERIALS............................................................................................. 24 
3.1.2 Fluorescence anisotropy assay .................................................................... 24 
3.1.3 Radioligand binding assay .......................................................................... 25 
3.1.4 Data analysis .............................................................................................. 26 
3.2 RESULTS ......................................................................................................... 28 
3.2.1 Characterization of binding of A2-TAMRA to D3R .................................... 28 
3.2.2 Determination of equilibrium dissociation constant (Kd) and concentration of 
available binding sites of the receptor (Bmax) with [
3H]-methylspiperone ................. 28 
3.2.3 Comparison of selectivity of A2-TAMRA for D3R compared to D1R ......... 29 
5 
 
3.2.4 Competition binding between D3R ligands and A2-TAMRA and [3H]- 
methylspiperone ...................................................................................................... 31 
3.2.5 Correlation of affinities from FA and radioligand binding assay ...................... 32 
3.3 DISCUSSION ................................................................................................... 34 
SUMMARY .................................................................................................................... 37 
REFERENCES................................................................................................................ 39 
Supplementary ................................................................................................................ 49 
NON-EXCLUSIVE LICENCE TO REPRODUCE THESIS AND MAKE THESIS PUBLIC




TERMS, ABBREVIATIONS AND NOTATIONS 
7TM: seven transmembrane 
AC: adenylyl cyclase 
BBV: budded baculovirus 
Bmax: concentration of available binding sites 
cpm: counts per minute 
D3R: Dopamine D3 receptor 
DMSO: dimethyl sulfoxide 
DTT: dithiothreitol 
ECL: extracellular loop 
EDTA: Ethylenediamine tetraacetic acid 
EGFR: epidermal growth factor receptor 
FA: fluorescence anisotropy 
GDP: guanosine diphosphate 
GPCR: G protein-coupled receptor 
GTP: guanosine triphosphate 
ICL: intracellular loop 
IC50: molar concentration of an unlabeled ligand that inhibits binding of a labeled ligand by 
50% 
Kd: equilibrium dissociation constant of a labelled ligand-receptor complex  
Ki: inhibition constant, used to refer to the equilibrium dissociation constant of an unlabelled 
ligand-receptor complex  
koff: dissociation rate constant 
kon: association rate constant 
MAPK: mitogen-activated protein kinase 
MSN: medium spiny neuron 
PIC: protease inhibitor cocktail 
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RET: resonance energy transfer 
Sf9: Spodoptera frugiperda cell line 
TAMRA: tetramethylrhodamine 
TFI: total fluorescence intensity 
Tris: 2-amino-2-(hydroxymethyl)propane-1,3-diol 






Cell signalling is a crucial process for normal growth and development of a cell. It enables 
cells to respond to several environmental cues or stimuli (Tuteja, 2009). The stimulus can 
be a physical or chemical signal which is received by specific proteins and converted to a 
cellular response through a series of molecular events. This process is known as signal 
transduction (Nelson and Cox, 2017). Proteins that are responsible for detecting these signals 
and relaying the effects of the signal are known as receptors and they bind to specific 
chemical compounds called ligands. Receptors can be divided into intracellular or 
transmembrane receptors. G protein - coupled receptors (GPCRs) constitute the largest and 
most diversified transmembrane receptor family in the mammalian genome (Luttrell, 2006). 
They recognize several endogenous as well as exogenous cues such as odorants, light, ions, 
metabolites, and neurotransmitters (Farooqui and Farooqui, 2016).  
Dopamine receptors (DRs) belong to the family of GPCRs and they are divided into five 
different subtypes namely, D1-5 receptors. Dopamine receptors play important roles in the 
central nervous system as well as in the periphery where they are involved in crucial 
functions such as voluntary movement, reward, hormonal regulation (Beaulieu and 
Gainetdinov, 2011). Pharmacological agents targeting dopaminergic neurotransmission 
have been clinically used for treating various neurological and psychiatric disorders, such as 
Parkinson’s disease, schizophrenia, bipolar disorder, Huntington’s disease, attention deficit 
hyperactivity disorder (ADHD1), and Tourette’s syndrome (Beaulieu and Gainetdinov, 
2011). Interactions of ligand binding to dopamine receptors can be studied through different 
ligand binding assays. 
In this thesis, we characterized ligand binding to Dopamine D3 receptor through fluorescence 
anisotropy assay and radioligand binding assay. We used a novel fluorescent ligand, A2-
TAMRA, for fluorescence anisotropy assay and compared the results from fluorescence 
anisotropy assay with radioligand binding assay. We also studied selectivity of A2-TAMRA 
for D3 receptor compared to D1 receptor. Budded baculoviruses obtained from Sf9 cells were 
used as receptor source in all the experiments.  
9 
 
1 LITERATURE REVIEW 
1.1 G protein - coupled receptor structure and classification 
Most GPCRs possess seven transmembrane (7TM) α helices connected by alternating 
intracellular and extracellular loop (ICL and ECL) regions, an amino terminus and a 
carboxyl terminus (Figure 1) (Rosenbaum et al., 2014). The greatest similarity among the 
various GPCRs is observed in the transmembrane regions while the most variable structures 
are the amino terminus, followed by carboxyl terminus and intracellular loop between 
transmembrane helices five and six (Kobilka, 2007). GPCRs in the human genome are 
generally classified into five families according to similarities in their sequence: rhodopsin 
(family A), secretin (family B), glutamate (family C), adhesion (family D) and frizzled/taste 
2 (family E) (Fu et al., 2014). The rhodopsin family containing four main groups (α, β, γ and 
δ) with 13 subbranches, is the largest family (Fu et al., 2014). Individual GPCRs have 
distinct signal transduction pathways, involving several G protein subtypes as well as G 
protein independent signaling pathways, thus it has been suggested to use the appellation 
7TM receptors instead of GPCRs (Kobilka, 2007). 
 
 
Figure 1. Structure of bovine rhodopsin. (A) Two-dimensional model of bovine rhodopsin. 
Grey cylinders represent the transmembrane helices. The ICLs and ECLs are shown. (B) The three-
dimensional model of rhodopsin (Jacob and Bunnett, 2006). 
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1.1.1 GPCR signalling through G proteins 
G proteins are heterotrimeric guanine nucleotide-binding proteins, consisting of α, β, and γ 
subunits (Luttrell, 2006). Guanosine diphosphate (GDP) is bound to the α subunit of a G 
protein when it is in an inactivated state (Jackson, 1991). Upon agonist binding to the GPCR, 
it undergoes conformational changes and activates the G protein, catalyzing dissociation of 
GDP from the G protein and association of guanosine triphosphate (GTP) with the α subunit 
(Jackson, 1991). This results in the dissociation of the G protein subunits from each other 
and from the receptor, generating a monomeric α subunit and a βγ dimer (Jackson, 1991). 
These can then regulate the activity of specific effectors which include second-messenger 
generating enzymes or specific ion channels (Gainetdinov et al., 2004). The subunits become 
reassociated together and thus, deactivated after hydrolysis of GTP to GDP and inorganic 
phosphate (Jackson, 1991). G proteins can be classified into four subtypes on the basis of 
the structure and function of alpha subunits: Gs, Gi/o, Gq/11, G12/13. The Gs class has a role in 
activation of adenylyl cyclase (AC), the Gi/o class inhibits AC and regulates ion channels, 
the Gq/11 activates phospholipase C and G12/13 is involved in activation of the Na
+/H+ 
exchanger pathway (Li et al., 2012). 
Ligands that bind to the GPCR active site can be classified based on the effect that they have 
on receptor function. An agonist is a ligand that binds to the receptor, altering its state and 
producing a biological response (Neubig et al., 2003). Agonists are divided into full agonists 
and partial agonists, depending on the extent of the response produced. A full agonist 
produces maximal response, whereas a partial agonist produces submaximal response and it 
cannot produce maximal response even at high concentrations (Neubig et al., 2003). The 
maximal response is the maximal response that can be obtained by the endogenous ligand 
for that particular receptor. The effect of an agonist can be reduced by an antagonist, which 
binds to the receptor without mediating cellular response (Berg and Clarke, 2018). Receptors 
can also be active without an activating ligand and thus, they display constitutive activity 
(Benovic et al., 1985; Berg and Clarke, 2018). Inverse agonists are ligands that can decrease 
the constitutive activity of a receptor (Berg and Clarke, 2018).  
1.1.2 GPCR desensitization and internalization 
Continued or overstimulation of GPCRs can be harmful to cells and can result in 
uncontrolled cell growth (Rajagopal and Shenoy, 2018). The desensitization of a GPCR 
response can be described as the loss of response subsequent to prolonged or repeated 
administration of an agonist (Hausdorff et al., 1990). The term `prolonged´ can be quite 
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misleading as experimentally, it can refer to a time duration ranging from seconds to hours 
(Kelly et al., 2008). Desensitization of the receptor involves phosphorylation of the receptor 
followed by β-arrestin binding. Desensitization can be homologous or heterologous. In the 
case of heterologous desensitization, the receptor does not need to be bound by an agonist, 
it just requires kinase activation by different stimuli (Pierce and Lefkowitz, 2001). Second 
messenger-dependent protein kinases, such as cAMP-dependent protein kinase and protein 
kinase C phosphorylate the receptor in this case (Pierce and Lefkowitz, 2001). GPCR kinases 
(GRKs) are involved in homologous receptor desensitization. It is known as homologous 
desensitization since the only substrates for GRKs are agonist-occupied receptors, thus 
ensuring the desensitization of only those receptors that have been activated (Pierce and 
Lefkowitz, 2001). Binding of arrestins is involved in both fast desensitization of the receptor 
as well as receptor internalization (Krupnick and Benovic, 1998; Pitcher et al., 1998). β-
arrestin binding is crucial for the internalization of many GPCRs as they act as adaptors 
linking the receptors to clathrin-coated pits (Ferguson et al., 1996).  
GRKs and arrestins can also act as signaling switches, giving rise to signaling pathways that 
are G protein-independent (Hall et al., 1988; Luttrell et al., 1999). For instance, arrestins can 
act as adaptors that induce the scaffolding of several signaling proteins including, mitogen-
activated protein kinases (MAPK) and protein kinase B (Akt) (Beaulieu et al., 2009; Shenoy 
and Lefkowitz, 2003, 2005).  
1.2 The dopaminergic system 
Dopamine forms part of a group of neurotransmitters called catecholamines (Vallone et al., 
2000). Catecholamines are characterized by a benzene ring with two adjacent hydroxyl 
groups, a single amine group and a side chain of ethylamine or one of its derivatives (Rondou 
et al., 2010) (Figure 2). The brain dopaminergic system comprises dopamine containing 
nuclei (substantia nigra pars compacta, ventral tegmental area, and arcuate nucleus) and the 
target areas (cortex, basal ganglia, thalamus, limbic structures, and pituitary gland) (Prieto, 
2017). Within the central nervous system, dopamine synthesis occurs in the cytosol of 
dopaminergic neurons and begins with hydroxylation of L-tyrosine by tyrosine hydroxylase 
to produce L-3,4-dihydroxyphenylalanine (L-DOPA), followed by its decarboxylation to 




Figure 2. Dopamine structure. (Pubchem, 2021) 
1.2.1 Dopamine receptors 
The effects of dopamine are mediated by dopamine receptors (DRs), which are a subclass of 
GPCRs. DRs are further divided into two classes: D1-like and D2-like, based on their 
structural, pharmacological and biochemical properties.  
Members of the same class of DR have significant homology within their transmembrane 
regions but distinct pharmacological properties (Beaulieu and Gainetdinov, 2011). D1-like 
receptors, consisting of D1 and D5 receptors couple to stimulatory G protein alpha subunits 
Gs, activating AC, while D2-like receptors couple to inhibitory G protein alpha subunits Gi/o 
inhibiting AC (Chien et al., 2010). The different dopamine receptors have different affinities 
for dopamine, ranging from nanomolar to micromolar range (Beaulieu and Gainetdinov, 
2011). D1-like receptors are found only post synaptically on dopamine-receptive cells, such 
as GABAergic medium spiny neurons (MSNs) in the striatum while D2-like receptors are 
found both pre- and post-synaptically (Rondou et al., 2010; Sokoloff et al., 2006). 
Structurally, D1-like and D2-like receptors have the same number of amino acids in the NH2 
terminal domain but the COOH terminal domain for D1-like receptors is longer than for D2-
like receptors (Missale et al., 1998). At the genetic level, the two classes of DRs differ 
primarily in the presence of introns in the dopamine receptor gene coding sequence 
(Gingrich and Caron, 1993). There are no introns in the D1 and D5 receptor genes, but the 
genes encoding D2-like receptors have several introns (Gingrich and Caron, 1993). DR 
subtypes also differ in their expression pattern in the brain and in the periphery. D1Rs are the 
most widely expressed in the human central nervous system (CNS), followed by D2, D3, D5 
and D4Rs (Mishra et al., 2018). In the periphery, all subtypes of DRs have been found in 
varying proportions in the kidney, adrenal glands, sympathetic ganglia, gastrointestinal tract, 
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blood vessels, and heart (Li et al., 2006; Missale et al., 1998; Svennilson and Aperia, 2000; 
Villar et al., 2009; Witkovsky, 2004). 
All DR subtypes can form homo and heterodimers in vivo, just like many GPCRs (Martel 
and McArthur, 2020). These impact the signal transduction pathway of the dopamine 
receptor (Martel and McArthur, 2020). The regions involved in DR dimerization are 
transmembrane domains 5 and 6 (Martel and McArthur, 2020). This interaction can be a 
transient process and can be stabilized with agonists like dopamine or quinpirole (Kasai et 
al., 2018). DR heterodimers which are most commonly observed in vivo are D1-D2, D1-D3, 
D1- Histamine H3 and D2- Adenosine A2A (Borroto-Escuela and Fuxe, 2019). They all have 
an effect on the MAPK response of these receptor systems, and D1-D3 can also modify the 
mechanism of β-arrestin recruitment and heterodimer internalization (Martel and McArthur, 
2020). 
Dopamine receptors mediate a lot of important functions such as locomotion, cognition, 
affect, attention, impulse control, decision making, motor learning, sleep, reproductive 
behaviors, and the regulation of food intake (Di Chiara and Bassareo, 2007; Iversen and 
Iversen, 2007; Koob and Volkow, 2010; Missale et al., 1998; Rondou et al., 2010). Other 
functions mediated by dopamine receptors that are localized outside the central nervous 
system include olfaction, vision, and hormonal regulation, such as the pituitary D2 dopamine 
receptor-mediated regulation of prolactin secretion, kidney D1R-mediated renin secretion, 
adrenal gland D2R-mediated regulation of aldosterone secretion, the regulation of 
sympathetic tone, D1, D2, and D4 receptor- mediated regulation of renal function, blood 
pressure regulation, vasodilation, and gastrointestinal motility (Iversen and Iversen, 2007; 
Li et al., 2006; Missale et al., 1998; Svennilson and Aperia, 2000; Villar et al., 2009; 
Witkovsky, 2004). 
1.2.1.1 D3 receptor 
D3R was first cloned in 1990 (Sokoloff et al., 1990). Compared to other subtypes of the D2-
like receptors, D3R has a limited pattern of distribution in the brain, the highest level of 
expression being observed in the limbic areas, such as in the shell of the nucleus accumbens, 
the olfactory tubercle, and the islands of Calleja (Missale et al., 1998; Sokoloff et al., 2006). 
D3R is also detectable at considerably lower levels in the striatum, the substantia nigra pars 
compacta, the ventral tegmental area, the hippocampus, the septal area, and in various 
cortical areas (Beaulieu and Gainetdinov, 2011).  
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At postsynaptic level in MSN, D3R modulates Ca
2+ channels through Phospholipase C, and 
protein phosphatase 2B (Martel and McArthur, 2020). At extra-synaptic location (in cell 
bodies), D3Rs are involved in selective modulation of Ca
2+ influx through low-voltage 
activated (CaV3, T-type) Ca2+ channels, in a β-arrestin-dependent pathway (Martel and 
McArthur, 2020). D3R turnover is regulated by the epidermal growth factor receptor (EGFR) 
tyrosine kinase signaling cascade (Sun et al., 2018). This is achieved by phosphorylation of 
GRK2 by EGFR, the GRK2 then phosphorylates the intracellular domain of the D3R to 
promote D3R intracellular receptor degradation (Sun et al., 2018). Compared to D2R, D3R 
undergoes limited agonist mediated receptor internalization (Kim et al., 2001).  
D3Rs are a target of interest for treatment of neuropsychiatric disorders and drug addiction. 
D3R has similar signal transduction mechanisms to D2R, they both couple to inhibitory G 
protein alpha subunits Gi/o. Inhibition of D2R signalling pathways is important for obtaining 
antipsychotic effects, but is associated with harmful effects on motor functions, causing 
extrapyramidal effects (Joyce and Millan, 2005). Thus, DR antagonists which are selective 
for D3R over D2R are not expected to produce these effects and this has been demonstrated 
with several D3R selective antagonists (Silverdale et al., 2004). The link between drug 
addiction and D3R has been established through evidence showing neuroplasticity changes 
in drug addicted subjects, such as the increase in D3R density in cocaine addicts and 
methamphetamine polydrug users (Le Foll et al., 2014).  
1.2.2 D3R ligands 
Several D3R ligands have been developed, with therapeutic potential for treatment of drug 
addiction and neuropsychiatric disorders. Some of the early D3R selective ligands that have 
attracted interest include BP897, NGB2904, and FAUC 365 (Bettinetti et al., 2002; Xi and 
Gardner, 2007; Yuan et al., 1998). Studies done with NGB2904 have shown that it inhibited 
cocaine self administration, cocaine-seeking behaviour and other addictive drug-enhanced 
brain stimulation reward (Xi and Gardner 2007). RGH-188, another D3R selective ligand, 
also known as cariprazine, was shown to diminish the reward effect of cocaine and decreased 
cocaine relapse (Román et al., 2013). It was approved in 2015 in the USA for the treatment 
of schizophrenia and bipolar disorders under the brand name Vraylar (Maramai et al., 2016).  
D3R ligands can also be labelled with a radioisotope or a fluorescent dye to study receptor- 
ligand binding interactions. Radioligands have been used for a long period of time for 
studying ligand binding to D3R. Radioligands have been used for characterizing receptors in 
their natural environment and those transfected into cell lines; studying receptor dynamics 
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and localization; identifying novel chemical structures that interact with receptors; and for 
defining ligand activity and selectivity in normal and diseased tissues (McKinney and 
Raddatz, 2006). However, there are safety concerns with radioligands and studying receptor-
ligand binding kinetics with radioligands is very labour intensive. Thus, fluorescent ligands 
have proven to be more promising to study receptor- ligand binding interactions (Stoddart 
et al., 2015). Fluorescent ligands can be used together with microscopy for studying cellular 
and tissue localisation of receptors (Sabirsh et al., 2005). Additionally, fluorescent ligands 
can be used for studying receptor ligand binding kinetics, to probe receptor organization in 
the membrane and to study dimerization (Tabor et al., 2017). However, there are very few 
fluorescent ligands available for studying D3R (Allikalt et al., 2020, 2021).  
1.3 Receptor ligand binding assays 
The aim of receptor ligand binding assays is to study interactions between ligands and 
receptors. The principal aspects of receptor-ligand binding interactions include binding 
affinity and kinetics, conformations of targets, binding thermodynamics, and ligand 
efficiency. Each aspect can be analysed using a different ligand binding assay (Yakimchuk, 
2011).  
For labelled ligand binding assays, it is crucial to ensure that the labelled ligand is actually 
bound to the receptor, irrespective of the type of experiment performed (Flanagan, 2016). 
Most labelled ligands bind, to some extent, to cell membranes, proteins, plastic or glassware 
present in the assay, in addition to the receptor (Flanagan, 2016). Binding to sites other than 
the receptor active binding site is known as nonspecific binding. The total binding measured 
in the experiment is the sum of specific and nonspecific binding of the labelled ligand. In 
general, nonspecific binding of the labelled ligand is considered to be linear and non-
saturable, thus, nonspecifically bound labelled ligand is not displaced even if excess of 
unlabeled ligand is used (Bylund and Toews, 2011; Hulme and Trevethick, 2010). Therefore, 
nonspecific binding is usually measured by adding excess of unlabelled competitive ligand 
so that it occupies all the receptor binding sites, and prevents the labelled ligand from binding 
to the receptor, but does not affect interactions of the labelled ligand with nonspecific 
binding sites (Flanagan, 2016). This measure of nonspecific binding is then subtracted from 
total binding to calculate specific binding of the labelled ligand to the receptor.  
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1.3.1 Kinetic aspects of receptor-ligand binding assays 
The relationship between the labelled ligand L, the free receptor R, and the receptor-labelled 
ligand complex RL, can be described by the simple reversible reaction (Jong et al., 2005): 




 [RL]                                                                                              (1)                                                                   
where kON and kOFF are the association and dissociation rate constants respectively.  
At equilibrium, the rate of formation of receptor-ligand complex is equal to the rate of dis-
sociation of receptor-ligand complex: 
kON x [R] x [L] = kOFF x [RL]                                                                                                (2) 







                                                                                                                  (3) 
Introduction of an unlabelled ligand which is competing for the receptor binding site 
(competitor ligand) leads to the formation of two types of receptor complexes: receptor-
labelled ligand complex, and receptor-competitor complex. The competitor displaces certain 
amount of the labelled ligand and this depends on both the concentration of the competitor 
and its affinity for the receptor (Jong et al., 2005).  
Incubation of a series of concentration of the competitor in the presence of fixed 
concentrations of the receptor and the labelled ligand, generates inhibition curves from 
which IC50 values can be found. IC50 values describe the concentration of competitor which 
displaces 50 % of bound labelled ligand from the receptor (Jong et al., 2005).  
The IC50 value is related to the affinity constant Ki of the competitor by the Cheng-Prusoff 
equation (Cheng and Prusoff, 1973): 
IC50 = Ki × (1 +  
[L]
𝐾d
)                                                                                                (4)     
where Kd is the equilibrium dissociation constant of the labelled ligand-receptor complex, 
and [L] is the concentration of the labelled ligand used in the assay. 
Since Cheng-Prusoff equation is derived from enzymatic reactions, it is based on some 
assumptions when used in the context of ligand binding assay: the system should be at 
equilibrium, binding should be reversible, the competitor and labelled ligand should bind to 
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the same site and there is no significant depletion of labelled ligand nor competitor upon 
binding to the target (Newton et al., 2008).  
Radioligand binding assay is done with large excess of the radioligand compared to the 
receptor. Thus, the free radioligand concentration is almost equal to the total concentration 
of radioligand [L]total. The total concentration of the radioligand used in each experiment is 
a known value, as it is measured during each experiment. 






, where [R]total is the concentration of receptor 
added.  
Saturation of the receptor binding sites with high amount of labelled ligand enables us to 
find the concentration of specific binding sites on the receptor. This parameter describes the 




                                                                                                (5)                                                                                                              
When [𝐿]𝑡𝑜𝑡𝑎𝑙  is equal to Kd, then [𝑅𝐿] = Bmax/2, thus, Kd describes the concentration of 
the radioligand at which 50% of the receptors are occupied by it. 
1.3.2 Radioligand binding assay 
Radioligand binding assay, first developed by Paton and Rang (Paton and Rang, 1965) has 
been thereafter used extensively in GPCR studies. Radioligand binding assay usually 
involves incubation of a receptor preparation with a radiolabeled ligand for a specific period 
of time at a specific temperature. The receptor bound radioligand is then separated from the 
free radioligand, usually by filtration (McKinney and Raddatz, 2006). The amount of bound 
radioligand to the receptor is then measured using liquid scintillation spectroscopy 
(McKinney and Raddatz, 2006) (Figure 3). The radioactivity count obtained from the 
receptor bound radioligand describes the total binding.  
The choice of radioisotope is a crucial aspect in the synthesis of the radioligand to be used 
in radioligand binding assay. Radio isotopes such as 3H, 125I are frequently used for labelling 
ligands. They have slow radioactive decay because of their long half life (12.4 years), thus 
they can be stored and used for long periods (Jong et al., 2005). Moreover, they can be used 




The major advantages of radioligand binding assay include sensitivity, specificity and ease 
of use (Jong et al., 2005). The major disadvantages of these assays are that radioactivity 
requires disposal of radioactive wastes and can also be a health hazard, and the need to 
separate free from bound ligand, which make these assays labour-intensive and relatively 
slow (Schnurr et al., 2006). Scintillation proximity assay is an alternative method that 
doesn’t require separation of bound and free radioligand. In scintillation proximity assay, 
the receptor is immobilized on a solid surface (bead) which contains a scintillant and the 
ligand is labelled with a radioactive isotope. In this method, only the radioligand bound to 
the scintillation beads can cause light emission from the bead, thus there is no need to 
separate the free and bound radioligand (Schnurr et al., 2006). However, scintillation 
proximity assay is more time consuming than filtration based assay (Jong et al., 2005).  
 
 
Figure 3. Procedure for filtration based radioligand binding assay. The receptor 
preparation and radioligand are incubated for a specific period of time at a specific temperature. The 
reaction is stopped by separating the receptor-bound radioligand from the free radioligand by vacuum 
filtration. Scintillant is then added to the filtermat containing the bound radioligand. The β particles 
emitted during radioactive decay interact with the scintillant to produce light which is detected by a 
luminescence counter (Auld et al., 2012) 
1.3.3 Fluorescence anisotropy assay 
Fluorescence anisotropy (FA) assay is a powerful method for studying ligand binding to 
receptors. FA assay is based on selective excitation of a subpopulation of fluorophores (a 
phenomenon known as photoselection) and monitoring the polarized emission (Shepherd 
and Fuentes, 2011). Plane polarized light from an appropriate polarizer is used to excite the 
sample and the fluorophore molecules having absorption transition dipole parallel to the 
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electric field vectors of the photons are more likely to get excited (Rinken et al., 2018). The 
excited molecules then emit polarized light with an electric field vector parallel to the 
emission transition dipole of the molecules (Rinken et al., 2018). There is partial 
depolarization of the emitted light if the molecules have rotational freedom (Rinken et al., 
2018). The extent of depolarization can be characterized by measuring the change in 
fluorescence anisotropy r: 




                                                                                                                                                     (a) 
                                                                               
where I|| is the fluorescence intensity when the excitation and emission polarization are 
parallel, I⊥ is the fluorescence intensity when the excitation and emission polarization are 
perpendicular. 
The total fluorescence intensity (TFI) is calculated as shown in (b): 
TFI = I|| + 2 x I⊥                                                                                                                                                                                                                     (b) 
Fluorescence anisotropy is related to the rotational correlation time 𝜏𝑐 (the average time 
taken by a molecule to rotate one radian) of the fluorescent particle and the fluorescence 
lifetime of the fluorophore 𝜏 by the Perrin’s equation: 






  (c) 
where r0 is the value of anisotropy at t = 0 after short pulse excitation (Shepherd and Fuentes, 
2011). 
For spherical molecules, the rotational correlation time is related to the molecular weight 
(M) of the molecule of interest according to the following equation:                                                                                                                                                                                                                                                   
𝜏𝑐 =  
ηM?̅?h
𝑅𝑇
                                                                                                                               (d) 
where 𝜂 is the viscosity of the solution, ?̅?h is the specific volume of a hydrated molecule, R 
is the universal gas constant, and T is the absolute temperature (Shepherd and Fuentes, 
2011). 
These equations demonstrate that fluorescence anisotropy depends directly on the 
fluorophore’s excited state lifetime τ and the rotational correlation time 𝜏𝑐. When a 
fluorescent ligand binds to a GPCR, the size of the fluorescent particle increases, the 
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fluorescent particle rotates slower, thus generating high fluorescence anisotropy value 
(Figure 4). 
The choice of fluorescent ligand is an important aspect of FA assay. A fluorescent ligand 
consists of a fluorophore and a pharmacophore. The attachment of the fluorophore to the 
pharmacophore should be rigid enough to prevent the fluorophore from rotating 
independently of the pharmacophore (Jameson and Ross, 2011). Additionally, the 
hydrophobicity of the fluorophore should be taken into account as it impacts the amount of 
nonspecific binding (Hughes et al., 2014). Other important features that need to be 
considered include the fluorescence lifetime, excitation wavelength, quantum yield, 
extinction coefficient of the fluorophore (Lea and Simeonov, 2011). The fluorescence 
lifetime of the fluorophore (the time lapse between excitation of the fluorophore and 
fluorescence emission) should be close to the rotational correlation time of the molecule 
being studied to achieve a good fluorescence anisotropy signal to noise measurement 
(Gijsbers et al., 2016). The excitation wavelength of the fluorophore should be on the red 
side of the visible light spectrum to prevent autofluorescence (Jong et al., 2005). The 
quantum yield of the fluorophore (ratio of the number of emitted photons to the number of 
absorbed photons) and the molar extinction coefficient should also be as high as possible 




Figure 4. Principle of FA assay. Polarized light from a polarizer is used to excite a subpopulation 
of fluorophores. Binding of the fluorescent ligand to the receptor causes it to rotate slower, resulting 
in high fluorescence anisotropy, whereas the free fluorescent ligand in solution rotates fast and as a 
result the emitted light becomes highly depolarized, giving rise to low fluorescence anisotropy 
(Rinken et al., 2018). 
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1.4 Sf9/Baculovirus expression system 
The source of receptors is a crucial aspect of receptor ligand binding assays. Due to the low 
natural abundance of GPCRs, heterologous expression of GPCRs is required (Massotte, 
2003). GPCRs have been expressed in E.coli, yeast cells and mammalian cell lines 
(Massotte, 2003). The drawbacks of using bacteria for GPCR expression are the incapability 
of bacteria to perform necessary post-translational modifications important for protein 
function, lack of G proteins, and low expression levels (Massotte, 2003). Yeast cells are 
capable of performing post translational modifications similar to other more complex 
eukaryotic cells, but N-glycosylation of mammalian membrane proteins in yeast is not 
effective (Massotte, 2003). Mammalian cell lines such as CHO, HEK293, BHK-21 have 
been used for expressing GPCRs since they can perform the necessary post translational 
modifications, however, protein yields are low and scaling up is costly (Massotte, 2003; 
Saarenpää et al., 2015). Thus, a more effective system is required. Over-expression of 
GPCRs in insect cells has proven to be very efficient due to low maintenance requirements 
and the ability of insect cells to the required post translational modifications (Aloia et al., 
2009).  
Baculoviruses are enveloped, large double-stranded DNA viruses which mainly infect 
insects (Wang et al., 2016). The two insect cell lines widely used for GPCR expression are 
Sf21 and Sf9 derived from Spodoptera frugiperda ovarian tissue (Aloia et al., 2009). These 
cell lines enable replication of the baculovirus Autographa californica multiple nuclear 
polyhedrosis virus which expresses the transgene encoding the GPCR during the viral 
infection and replication process (Aloia et al., 2009). In the Sf9/baculovirus expression 
system, the cDNA encoding the GPCR is first placed into a plasmid transfer under the 
polyhedrin promoter as the latter is a very strong promoter, and is not necessary for viral 
propagation in cell culture (Schneider and Seifert, 2010). Then, there is site specific 
transposition of the plasmid into a baculovirus shuttle vector (bacmid) (Luckow, 1993; 
Saarenpää et al., 2015). This bacmid is then propagated into E.coli bacteria, purified and 
transfected into Sf9 cells to produce recombinant baculoviruses (Saarenpää et al., 2015). 
During the insect cell infection cycle, budded baculoviruses (BBV) are formed as 
nucleocapsids which bud from the insect cell surface (Veiksina et al., 2014). Baculoviruses 
have a double lipid bilayer envelope derived from the Sf9 cell surface, containing membrane 
proteins from the host cell surface (Veiksina et al., 2014). The budded baculoviruses can be 
22 
 
separated from the Sf9 cells by centrifugation and used as a source of receptor for ligand 
binding assays (Veiksina et al., 2014).  
Work involving baculoviruses are done on Biosafety Level 1, thus they are neither dangerous 








2 THE AIMS OF THE THESIS 
D3R receptor has been studied extensively using radioligand binding methods. However, 
there are very few fluorescent ligands that are available for studying D3R. A2-TAMRA is a 
novel fluorescent ligand with a pharmacophore that has subnanomolar affinity for D3R. 
Since there hasn’t been previous success using other fluorescent ligands for characterizing 
D3R in FA assay, we decided to use it for FA assay. The radioligand [
3H]-methylspiperone 
has been previously used for studying ligand binding to D3R. So, we studied [
3H]-
methylspiperone binding to D3R in parallel. Previous studies have shown that BBV is a good 
source of receptors for radioligand binding assay (Allikalt and Rinken, 2017). So, we used 
BBV as a receptor source in both assays. Since D1R has also been studied previously in FA 
assay using BBV and another fluorescent ligand (Allikalt et al., 2018), we wanted to 
compare how selective A2-TAMRA is for D3R compared to D1R. 
Thus, we performed the following experiments: 
● Competition binding experiments between D3R ligands and A2-TAMRA in FA assay 
for determination of affinities of known D3R ligands  
● Saturation binding experiment with D1R in FA assay to compare selectivity of A2-
TAMRA for D3R compared to D1R 
● Saturation binding experiments for determination of concentration of available 
binding sites of the receptor (Bmax) and the equilibrium dissociation constant (Kd) of 
the receptor-[3H]-methylspiperone complex 
● Competition binding experiments for determination of affinities of known D3R 






3 EXPERIMENTAL PART  
3.1 MATERIALS AND METHODS 
3.1.1 MATERIALS 
Reagents and receptor source 
MgCl2, KCl, CaCl2, NaCl, 2-amino-2-(hydroxymethyl)-1,3-propanediol (TRIS), HCl, 
dithiothreitol (DTT), ethylenediaminetetraacetic acid (EDTA) were from Applichem. 
Pluronic acid F-127 was from Sigma Aldrich and Na- HEPES was from Amresco. Complete 
EDTA free protease inhibitor cocktail (PIC) was from Roche Diagnostics.  
D3R ligands Quinpirole, 7-hydroxypipat maleate, 7-hydroxyDPAT hydrobromide, 
Sulpiride, Spiperone were from TOCRIS and Dopamine, Apomorphine, Butaclamol, 
Raclopride, Terguride were from Sigma Aldrich. Stock solutions of these ligands were 
prepared in DMSO (Applichem) or milli Q water.  
 [3H]-methylspiperone (83.8 Ci/mmol) was from Perkin Elmer.  
A2-TAMRA, the fluorescent ligand used in FA assay was synthesized by Dr Erki Enkvist 
and Hanna Riia Allas of University of Tartu based on FAUC 346 pharmacophore. Saturation 
binding experiments performed by Maris Johanna Tahk have shown that A2-TAMRA has a 
dissociation constant of 0.13 ± 0.03 nM. Kinetic studies have provided an average koff of (6 
± 3)× 10-4 s-1 and an average kon of (4 ± 4)× 10
-3 nM-1s-1. These rate constants were obtained 
with SB toolbox 2 (Schmidt and Jirstrand, 2006), modified by Tõnis Laasfeld (unpublished 
data).  
The source of receptor for this work was budded baculovirus particles (BBV) and BBV 
preparations done previously by Maris Johanna Tahk and Anni Allikalt were used in FA and 
radioligand binding assays. Description of budded baculovirus preparation is in (Allikalt and 
Rinken, 2017). 
3.1.2 Fluorescence anisotropy assay 
FA assay buffer consisted of 1 mM MgCl2, 5 mM KCl, 1 mM CaCl2, 135 mM NaCl, 0.1% 
pluronic acid F-127, Complete EDTA-free PIC (used according to manufacturer’s protocol), 
11 mM Na-HEPES (pH 7.4) and Milli-Q water.  
Stocks of the D3R ligands and fluorescent ligand were stored in DMSO at -20 °C and diluted 
with assay buffer on the day of experiment.  
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All competition binding experiments were done on black 96-well half Area, flat bottom 
Polystyrene NBS™ plates (Corning), with a final reaction volume of 100 µL in each well. 
Measurements were done in duplicates and at least three independent experiments were 
performed for each D3R ligand. Fixed concentrations of A2-TAMRA (1 nM) and BBV 
(volume of receptor stock in well = 5 µL) were incubated with serial dilutions of D3R ligands. 
All experiments had blank wells as well as positive control wells. Blank wells contained 
only assay buffer and same amount of BBV as in other wells. Positive control wells had only 
assay buffer, BBV, and fluorescent ligand. FA plates were measured for three hours using 
Synergy NEO plate reader (BioTek) at 27 °C, with polarizing excitation filter of 530 nm 
(bandwidth 30 nm) and dual emission of 590 nm (bandwidth 35 nm). 
For saturation binding experiment with D1R, serial dilutions of BBV were pipetted to two 
fixed concentrations of the fluorescent ligand (0.5 nM, and 3 nM). Nonspecific binding 
determined with 5 µM butaclamol and 30 µM butaclamol respectively. Total binding was 
determined in the absence of butaclamol. Blank wells having just assay buffer (50 µL) and 
BBV (50 µL) were included in the experiment. The plate was read for two hours in Synergy 
NEO plate reader (BioTek) at 27 °C, with polarizing excitation filter of 530 nm (bandwidth 
30 nm) and dual emission of 590 nm (bandwidth 35 nm). 
3.1.3 Radioligand binding assay 
All radioligand binding experiments were performed on round bottom 96-well plates 
(Greiner) and the final reaction volume in each well was 250 µL. The assay buffer consisted 
of 50 mM Tris-HCl, 120 mM NaCl, 5 mM MgCl2,5 mM KCl, 1 mM EDTA. Before the 
experiment, 1 mM DTT was added to the falcon tube in which assay buffer was prepared. 
For determination of Kd and Bmax, fixed amount of BBV (Volume of receptor stock in well 
= 1.88 µL) was added to two times serial dilutions of [3H]-methylspiperone (starting 
concentration in well = 10 nM). Nonspecific binding was determined in the presence of 1 
µM butaclamol and total binding was determined in the absence of butaclamol.  
For competition binding experiments, fixed amounts of BBV (volume of receptor stock in 
well = 0.94 µL) and [3H]-methylspiperone (concentration in well = 2.5 nM) were added to 
serial dilutions of D3R ligands. Measurements were done in triplicates and for some ligands 
we performed at least 3 independent experiments while for others we couldn’t perform three 
independent experiments, since we were running out of radioligand stock solution.  
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For all radioligand binding experiments, after the samples were added to the plate, the 
reaction medium was incubated for one hour at 25 °C on a shaker at 400 rpm. After that, the 
bound radioligand was separated from the free radioligand by filtration through thick glass 
fiber filtermats (Perkin Elmer) in FilterMate Harvester (Perkin Elmer). The filtermats were 
then washed five times with ice cold washing buffer (consisting of 20 mM potassium 
phosphate, 100 mM NaCl, pH =7.4). After that, the filtermats were dried in a microwave 
oven at 800W for two minutes. Solid scintillant MeltiLexTM B/HS was then melted onto the 
filtermats using MeltiLexTM Heatsealer. Radioactivity from the filters were measured with 
Wallac MicroBeta TriLux 1450 Luminescence Counter (Perkin Elmer). Total concentration 
of the radioligand was determined by pipetting 50 µL of the radioligand to vials containing 
3 ml scintillation fluid (Perkin Elmer) and measuring the radioactivity count from Wallac 
MicroBeta TriLux 1450 Luminescence Counter (Perkin Elmer).  
3.1.4 Data analysis 
FA assay 
Experimental data from FA was analysed with Aparecium 2.0.20 software 
(http://gpcr.ut.ee/aparecium.html) and data fitting was done on GraphPad Prism 5.04.  
Parallel and perpendicular fluorescence intensities from blank wells were subtracted from 
all intensities from all the other points before FA and TFI calculation.  
Data from saturation binding experiment was analyzed using a global model implemented 
in GraphPad Prism assuming a single binding site for the fluorescent ligand, the possibility 
of nonspecific binding, and a potential change in quantum yield upon binding (Veiksina et 
al., 2014). 
Data from competition binding experiments was analysed with Gen5 tools of Aparecium 
software. IC50 values were calculated using nonlinear fitting method from competition 
binding curves, generated by dose-response inhibition model in GraphPadPrism. pIC50 
values from FA competition binding experiments was converted to pKi values using Cheng-
Prusoff equation (Cheng and Prusoff, 1973).  
Radioligand binding assay 
The concentration of free radioligand in nanomolar was calculated using the formula: con-
centration of free radioligand (nM) = x counts per minute (cpm)/ (specific activity of radi-
oligand cpm/femtomol x Vfinal µL), where x is the value obtained from counting of total 
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radioligand concentration in vials, and Vfinal is the final reaction volume in each well. Non-
specific binding count was subtracted from total binding count to obtain count for specific 
binding. Specific binding count was converted to receptor concentration in nanomolar using 
the formula: C (receptor) = y cpm / (specific activity of radioligand CPM/femtomol x Vol-
ume of receptor stock in each well in µL), where y = count from specific binding.  
Data from saturation binding experiments was analysed using one site-specific binding 
model in GraphPad Prism.  
Data from competition binding experiments was analysed using one site-fit Ki model in 
GraphPad prism.  



















3.2 RESULTS  
3.2.1 Characterization of binding of A2-TAMRA to D3R 
We first characterized binding of A2-TAMRA to D3R with the speed at which FA increases 
in our experiments. Binding of A2-TAMRA to D3R caused an increase in FA for 
approximately 35 minutes in the case of total binding (Figure 5). We also got a very good 
signal window since the theoretical maximum value of FA is 0.4 (Lakowicz, 2006). 
In addition to FA, TFI increased upon binding of A2-TAMRA to the receptor 
(Supplementary Figure 1). There was an average increase of 15 ± 3 % in TFI upon binding 
of A2-TAMRA to D3R.  
 











Figure 5. FA change in time caused by binding of A2-TAMRA to BBV displaying the 
D3R. Nonspecific binding was determined with 316 µM 7-hydroxyDPAT hydrobromide. Total 
binding was determined in the absence of 7-hydroxyDPAT hydrobromide. FA took approximately 
35 minutes to increase in the case of total binding. For nonspecific binding, FA increased very rapidly 
in the first few seconds, and there was no significant increase in FA throughout the reaction. Data 
shows representative of at least three independent experiments done in duplicate. 
3.2.2 Determination of equilibrium dissociation constant (Kd) and 
concentration of available binding sites of the receptor (Bmax) with [3H]-
methylspiperone 
Saturation binding experiments were performed for determination of the Kd of [
3H]- 
methylspiperone-receptor complex and concentration of available binding sites of the 
29 
 
receptor (Bmax) for [
3H]-methylspiperone (Figure 6). The Kd value is also required for 
calculations of Ki of the unlabelled D3R ligands. Previous saturation binding experiments 
done with [3H]-methylspiperone in CHO cell lines expressing D3R have provided an average 
Kd of 0.6 ± 0.2 nM (Schmieg et al., 2016). Therefore we wanted to measure the Kd in BBV 
expressing D3R. Three independent experiments were performed; the average Kd was 0.7 ± 
0.2 nM, and the average Bmax was 35 ± 4 nM. 
 


































Figure 6. Binding of [3H]-methylspiperone to D3R on BBV. Serial dilutions of [
3H]-
methylspiperone were incubated with BBV (volume of receptor stock in well = 1.88 µL) for one 
hour; nonspecific binding was determined with 1 µM butaclamol and total binding was determined 
in the absence of butaclamol. Data shows mean ± S.E.M from a representative experiment of three 
independent experiments performed in triplicates.  
3.2.3 Comparison of selectivity of A2-TAMRA for D3R compared to D1R 
D1R on BBV has been previously studied in FA assay using another fluorescent ligand 
(Allikalt et al., 2018). Therefore, saturation binding experiment was performed with D1R to 
determine selectivity of A2-TAMRA for D3R compared to D1R. The pharmacophore of A2-
TAMRA is known to have a Ki value of 0.23 ± 0.02 nM with D3R and a Ki value of 670 ± 
15 nM with D1R (Bettinetti et al., 2002).  
For radioligand saturation binding experiments, we were able to use increasing 
concentrations of the radioligand. However, this approach doesn’t work with FA saturation 
binding experiments. FA is a ratiometric assay, which means that it depends on the ratio of 
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both free and bound fluorescent ligand to get a good signal (Rinken et al., 2018). Using 
excess of fluorescent ligand will increase the amount of unbound ligand, giving rise to a 
smaller change in FA. Thus, to measure Kd of a labelled ligand using FA, a different 
approach has to be used. This can be achieved by using two fixed concentrations of labelled 
ligand with serial dilutions of the receptor to provide increasing receptor concentration 
(Veiksina et al., 2014). This approach was previously used by Maris Johanna Tahk to 
determine Kd of A2-TAMRA with D3R (Figure 7A). The same approach was used to perform 
saturation binding experiment with D1R. Increasing the receptor concentration provided 
increase in FA with both concentrations of A2-TAMRA. However, even at higher 
concentration of A2-TAMRA, there was a very small difference between nonspecific and 
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Figure 7. Binding of A2-TAMRA to D1R and D3R on BBV. (A) Binding of A2-TAMRA to 
D3R. Serial dilutions of BBV were incubated with two fixed concentrations of A2-TAMRA (0.5 nM 
and 3 nM). Nonspecific binding was determined in the presence of 3 µM butaclamol and total binding 
was determined in the absence of butaclamol. Data shows representative experiment of four 
independent experiments done in duplicates. (B) Binding of A2-TAMRA to D1R. Serial dilutions of 
BBV were incubated with two fixed concentrations of A2-TAMRA (0.5 nM and 3 nM). Nonspecific 
binding was determined with 5 µM and 30 µM butaclamol respectively. Total binding was 
determined in the absence of butaclamol. 
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3.2.4 Competition binding between D3R ligands and A2-TAMRA and [3H]- 
methylspiperone 
Membrane preparations have been used previously as a source of receptor in radioligand 
competition binding experiments, but it has been shown previously that BBV preparations 
are also good receptor sources for radioligand binding assay (Allikalt and Rinken, 2017). 
Therefore, we used BBV as receptor source in both radioligand and FA competition binding 





















































Figure 8. Competition binding between the D3R ligands and A2-TAMRA or [
3H]- 
methylspiperone. (A) Competition binding between D3R ligands and A2-TAMRA. Fixed 
concentrations of BBV (volume of receptor stock in well = 5 µL) and A2-TAMRA (concentration in 
well = 1 nM) were incubated with serial dilutions of the competitor ligands for three hours. Data 
shows representative experiment of at least three independent experiments done in duplicates. (B) 
Competition binding between D3R ligands and [
3H]-methylspiperone. Fixed concentrations of BBV 
(volume of receptor stock in well = 0.94 µL) and [3H]- methylspiperone (concentration in well = 2.5 
nM) were incubated with serial dilutions of the competitors for one hour. Data shows mean ± S.E.M 
from a representative experiment of two to three independent experiments done in triplicates.  
The incubation time of three hours was chosen for FA since A2-TAMRA hasn’t been used 
with D3R in competition binding experiments before, so we wanted to be sure that the 
incubation time is enough for equilibrium to be reached. FA assay enables monitoring of the 
change in IC50 values in real time. This enables us to know at what time the IC50 values are 
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stable. For the D3R ligands ligands quinpirole, 7-hydroxypipat maleate, and raclopride, we 
noticed an intial drop in log IC50 in the beginning (Figure 9). 














Figure 9. Change in IC50 with time during displacement of A2-TAMRA by 7-
hydroxypipat maleate. LogIC50 was obtained from competition binding experiments where D3R 
ligands were competing with A2-TAMRA (concentration in well = 1 nM) for the receptor binding 
site. Data shows mean ± S.E.M. 
For radioligand binding assay, the incubation time of one hour was chosen since this 
incubation time has been previously reported with [3H]-methylspiperone (Schmieg et al., 
2016).  
3.2.5 Correlation of affinities from FA and radioligand binding assay  
To compare how consistent the two methods are with each other, the measured affinities of 
D3R ligands from both methods were compared with each other. Since IC50 values depend 
on labelled ligand concentration, the IC50 values from FA assay were first converted to pKi 
values using Cheng-Prusoff equation (Supplementary table 1) (Cheng and Prusoff, 1973). A 
very good correlation with very narrow confidence intervals (Figure 10) was obtained 
(unadjusted R2 of the correlation = 0.94) between both methods. Also, the uncertainty was 























Figure 10. Correlation between pKi obtained from FA assay and radioligand binding 
assay. Solid line shows linear regression of pKi values measured from FA and radioligand binding 
assay. Dashed lines show 95% confidence intervals. Vertical error bars show uncertainty limits for 



















Previous studies have shown that A2-TAMRA has a small Kd (materials section), implying 
high affinity for D3R. This is demonstrated by the speed of FA increase in the case of total 
binding of A2-TAMRA to D3R. Thus, A2-TAMRA is a suitable fluorescent ligand for 
screening known D3R ligands in FA assay. We also saw that, compared to D1R, A2-TAMRA 
is a D3R selective ligand.  
The pKi values from FA and radioligand binding assay were compared with previously 
determined pKi values (Burris et al., 1995; Chumpradit et al., 1994; Sautel et al., 1995; 
Freedman et al., 1994; MacKenzie et al., 1994; Mierau et al., 1995; Millan et al., 1995, 
2002; Sokoloff et al., 1990; Pugsley et al., 1995; Sokoloff et al., 1992; Tang et al., 1994; 
Van Tol et al., 1991) to see how consistent our results are with previously determined pKi 
values. pKi values from literature were determined in radioligand competition binding 
experiments and each reference used a different radioligand. Also, in literature, cell lines 
such as CHO, and HEK293 were used. These have mammalian G proteins, which can couple 
to the receptor. The difference between literature affinities and affinities from both 
radioligand binding assay and FA assay was bigger in the case of the full agonists quinpirole 
and dopamine. There was just one reference for the full agonist 7-hydroxypipat maleate in 
literature and the FA pKi was higher than that value. But the antagonists and partial agonists 
had a good correlation with literature data in the case of both radioligand binding and FA 
assay (unadjusted R2 of the correlation = 0.88) (supplementary figures 2,3B). Agonists 
display higher affinity for the receptor when G proteins are coupled to the receptor (De Lean 
et al., 1980; Gether, 2000). For this thesis, we used BBV as receptor source and these don’t 
have G proteins, which may be the reason why the full agonists didn’t have a good 
correlation with literature data. We nonetheless got a very good correlation between both 
methods and we saw that there is higher precision in the case of FA assay.  
FA assay has several advantages over radioligand binding assay. FA is a fast and 
homogeneous assay while radioligand binding assay is time consuming and it requires the 
wash and filtration step. Since FA is a real time assay, it enables measurement of association 
and dissociation rate constants of the fluorescent ligand. Measurement of association and 
dissociation rate constants can be very challenging with the filtration based radioligand 
binding assay. From our experiments, we could also observe an intial drop in logIC50 for 
some of the competitors. This could be a hint that the competitor ligand has slower binding 
kinetics compared to the fluorescent ligand. The binding kinetics of the competitors can also 
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be accurately measured using kinetic modelling, but this is subject for further studies. 
Additionally, FA is a high throughput assay, FA assay has been done in 384 well-plate 
format (Allen et al., 2000) as well as 1536 well-plate format (Harris et al., 2003). 
Since we were able to successfully use A2-TAMRA for screening the D3R ligands in FA 
assay, we can now consider other studies of D3R using A2-TAMRA. Studies of receptors 
using fluorescent ligand can be used to either directly measure fluorescence or indirectly 
measure resonance energy transfer (RET) (Soave et al., 2020). For Nano-bioluminescence 
resonance energy transfer (NanoBRET) binding assay, the Nanoluc, which is a genetically 
modified luciferase, is fused to the GPCR of interest (Grätz et. al., 2020). It requires a 
fluorescent ligand whose excitation spectrum should overlap with the bioluminescence 
spectrum of NanoLuc, as BRET acceptor (Grätz et. al., 2020). After binding of a fluorescent 
ligand to the luciferase-tagged GPCR, the fluorescent ligand emits light due to 
bioluminescence resonance energy transfer (Grätz et al., 2020). The use of the fluorophore 
TAMRA has been previously shown to be good with BRET-based assays (Hoare et al., 2019; 
Sakyiamah et al., 2019; Stoddart et al., 2015). In this work, we have shown that A2-TAMRA 
has very high affinity for D3R and since it has slow dissociation kinetics, it can be used to 
study D3R-ligand binding interactions in NanoBRET assay. NanoBRET assay can be used 
to study using receptor-ligand binding interactions in live cells as well and there is also less 
autofluorescence with NanoBRET assay (Brown et al., 2015; Dale et al., 2019).  
Confocal microscopic studies of specific fluorescent ligand binding may be used for analysis 
of the distribution of receptors in tissue sections (Beaudet et al., 1998). For studies using 
tissue sections, it is important to choose a fluorophore emitting in the red or far red region 
to avoid cellular autofluorescence (Stoddart et al., 2016). TAMRA is an orange dye, with 
excitation peak at 552 nm, and emission peak at 578 nm (Blommel et al., 2004). 
Fluorophores that emit in the far red area include cyanine 5 (Patsenker et al., 2011). 
However, it has a small fluorescence lifetime (Patsenker et al., 2011). Thus, it is not suitable 
even for FA assay. For fluorescent ligand binding to receptors in tissue sections, a fluorescent 
ligand with a small dissociation rate constant is preferred, so that it still remains bound to 
the receptor after the wash steps involved in fluorohistochemical studies. So, swapping 
TAMRA fluorophore with Cy5 would not be suitable for tissue sections. However, there are 
different reagents and treatments, such as sodium borohydride and Sudan Black B that can 
be used to reduce autofluorescence from tissues (Baschong et al., 2001).  
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Fluorescent ligands have been used in Total Internal Reflection Fluorescence (TIRF) 
microscopy-based assays to study receptor dimerization. TIRF microscopy is a wide field 
imaging technique involving excitation of fluorescent molecules within a thin section of a 
sample (Stoddart et al., 2015). Due to its sensitivity and restricted illumination, TIRF is 
excellent for single molecule imaging and for identifying individual receptors and receptor 
complexes in a timeframe of seconds to gain insight about their mobility and clustering (Hern 
et al., 2010). D3R forms dimers with D1R, and D2R and other GPCRs as well (Prieto, 2017). 
The results of the works for this thesis confirm that A2-TAMRA binds well to D3R in BBV 
and studies have shown that BBV works in FA as well as in TIRF assay (Laasfeld et al., 
2021). A2-TAMRA’s high affinity for D3R makes it a suitable candidate to be used in TIRF 
microscopy for single molecule imaging.  
In conclusion, we can say that the results of the FA assay show that it can be adapted to high-
thoughput format and we have validated the FA assay with a radioligand binding assay. The 
properties of A2-TAMRA opens up possibilities for studying D3R using other fluorescence-










Dopamine receptors, which consist of five different subtypes (Dopamine D1-5 subtypes) play 
important roles in the central nervous system as well as in the periphery. Due to its limited 
distribution, Dopamine D3 receptor is involved in emotional and cognitive functions. 
Abnormalities in D3 receptor signalling are linked to several neuropsychiatric disorders. 
Thus, there have been several efforts to develop several ligands targeting Dopamine D3 
receptor. Development of a ligand suitable for therapeutic use involves several studies 
including studies of kinetic properties, measurement of the affinity of the ligand for the 
receptor and structural studies.  
For a long time, Dopamine D3 receptor ligands have been labelled with a radioisotope for 
measuring affinities of unlabelled ligands for D3 receptor. These radioligands have also been 
used to study localisation of receptors in diseased tissues. However, studies of radioligand 
binding to receptors can be labour intensive and radioactivity experiments require disposal 
of radioactive waste and can represent a health hazard. Thus, fluorescent ligands have 
emerged as a more promising alternative for studying ligand binding to receptors. They have 
been used to study several other receptors, but there are limited fluorescent ligands available 
for studying dopamine D3 receptor. A2-TAMRA is a novel fluorescent ligand which has a 
pharmacophore that has been shown to have good affinity for D3 receptor.  
Fluorescence anisotropy assay is a powerful technique for studying ligand binding to 
receptors. Since there hasn’t been any successful fluorescent ligand for studying Dopamine 
D3 receptor in fluorescence anisotropy assay previously, we decided to use A2-TAMRA in 
fluorescence anisotropy assay. We used it to screen known unlabelled D3 receptor ligands in 
fluorescence anisotropy assay. We also screened those ligands in parallel in radioligand 
binding experiments with a radioligand ([3H]-methylspiperone) that has been previously 
used to study D3 receptor. We used budded baculoviruses as our receptor source in both 
assays since they have been previously shown to be a good receptor source for both 
fluorescence anisotropy and radioligand binding assay. We also investigated whether A2-
TAMRA would work in fluorescence anisotropy assay with another dopamine receptor as 
well (Dopamine D1 receptor). In the end, we compared the results of fluorescence anisotropy 
assay with the radioligand binding assay.  
We saw that A2-TAMRA binds well to D3 receptor displayed on budded baculoviruses and 
it prefers D3 receptor over D1 receptor. We also got a very good correlation between both 
methods. Fluorescence anisotropy assay can also be used to monitor ligand binding in real 
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time and kinetic properties can be accurately measured using kinetic modelling, but this 
remains subject for further study. The properties of A2-TAMRA make it a suitable candidate 
for further studies using nanobioluminescence resonance energy transfer, and total internal 







Allen, M., Reeves, J., & Geoffrey, M. (2000). High Throughput Fluorescence Polarization: 
A homogeneous Alternative to Radioligand Binding for Cell Surface Receptors. 
Journal of Biomolecular Screening, 5. 
Allikalt, A., Kopanchuk, S., & Rinken, A. (2018). Implementation of fluorescence 
anisotropy-based assay for the characterization of ligand binding to dopamine D1 
receptors. European Journal of Pharmacology, 839(September), 40–46. 
https://doi.org/10.1016/j.ejphar.2018.09.008 
Allikalt, A., Laasfeld, T., Ilisson, M., Kopanchuk, S., & Rinken, A. (2021). Quantitative 
analysis of fluorescent ligand binding to dopamine D3 receptors using live-cell 
microscopy. FEBS Journal, 288(5), 1514–1532. https://doi.org/10.1111/febs.15519 
Allikalt, A., Purkayastha, N., Flad, K., Schmidt, M. F., Tabor, A., Gmeiner, P., Hübner, H., 
& Weikert, D. (2020). Fluorescent ligands for dopamine -. Scientific Reports, 1–13. 
https://doi.org/10.1038/s41598-020-78827-9 
Allikalt, A., & Rinken, A. (2017a). Budded baculovirus particles as a source of membrane 
proteins for radioligand binding assay: The case of dopamine D1 receptor. Journal of 
Pharmacological and Toxicological Methods, 86(April), 81–86. 
https://doi.org/10.1016/j.vascn.2017.04.004 
Allikalt, A., & Rinken, A. (2017b). Budded baculovirus particles as a source of membrane 
proteins for radioligand binding assay: The case of dopamine D1 receptor. Journal of 
Pharmacological and Toxicological Methods, 86(November 2016), 81–86. 
https://doi.org/10.1016/j.vascn.2017.04.004 
Aloia, A., V.Glatz, R., McMurchie, E. J., & Leifert, W. R. (2009). GPCR Expression using 
Baculovirus-Infected Sf9 cells. In Methods in Molecular Biology (Vol. 552, Issue 2, pp. 
115–129). https://doi.org/10.1007/978-1-60327-317-6 
Auld, D. S., Farmen, M. W., Kahl, S. D., Kriauciunas, A., McKnight, K. L., Montrose, C., 
& Weidner, J. R. (2012). Receptor Binding Assays for HTS and Drug Discovery. In 
Assay Guidance Manual (pp. 1–42). http://www.ncbi.nlm.nih.gov/pubmed/22553864 
Baschong, W., Suetterlin, R., & Laeng, R. H. (2001). Control of Autofluorescence of 
Archival Formaldehyde-fixed , Paraffin-embedded Tissue in Confocal Laser Scanning 
Microscopy ( CLSM ). The Journal of Histochemistry and Cytochemistry, 49(12), 
1565–1571. 
Beaudet, A., Nouel, D., Stroh, T., Vandenbulcke, F., Dal-Farra, C., & Vincent, J. P. (1998). 
Fluorescent ligands for studying neuropeptide receptors by confocal microscopy. 
Brazilian Journal of Medical and Biological Research, 31(11), 1479–1489. 
https://doi.org/10.1590/S0100-879X1998001100017 
Beaulieu, & Gainetdinov, R. R. (2011). The Physiology, Signaling, and Pharmacology of 
Dopamine Receptors. Pharmacol Ogical Reviews, 63(1), 182–217. 
https://doi.org/10.1124/pr.110.002642.182 
Beaulieu, J., Gainetdinov, R. R., & Caron, M. G. (2009). Akt / GSK3 Signaling in the Action 
of Psychotropic Drugs. Annual Review of Pharmacology and Toxicology, 49, 327–349. 
https://doi.org/10.1146/annurev.pharmtox.011008.145634 
Benovic, J. L., Pike, L. J., Cerione, R. A., Staniszewski, C., Yoshimasa, T., Codina, J., 
Caron, M. G., & Lefkowitz, R. J. (1985). Phosphorylation of the Mammalian β -
40 
 
Adrenergic Receptor by Cyclic AMP-dependent Protein Kinase. The Journal of 
Biological Chemistry, 260(11), 7094–7101. https://doi.org/10.1016/S0021-
9258(18)88892-5 
Berg, K. A., & Clarke, W. P. (2018). Making sense of pharmacology: Inverse agonism and 
functional selectivity. International Journal of Neuropsychopharmacology, 21(10), 
962–977. https://doi.org/10.1093/ijnp/pyy071 
Bettinetti, L., Schlotter, K., & Gmeiner, P. (2002). Interactive SAR Studies : Rational 
Discovery of Super-Potent and Highly Selective Dopamine D3 Receptor Antagonists 
and Partial Agonists. J Med Chem, 45, 4594–4597. 
Blommel, P., Hanson, G. T., & Vogel, K. W. (2004). Multiplexing Fluorescence Polarization 
Assays to Increase Information Content Per Screen: Applications for Screening Steroid 
Hormone Receptors. Journal of Biomolecular Screening, 294–302. 
https://doi.org/10.1177/1087057104264420 
Borroto-Escuela, D. O., & Fuxe, K. (2019). Oligomeric Receptor Complexes and Their 
Allosteric Receptor-Receptor Interactions in the Plasma Membrane Represent a New 
Biological Principle for Integration of Signals in the CNS. Frontiers in Molecular 
Neuroscience, 12. https://doi.org/10.3389/fnmol.2019.00230 
Brown, N. E., Blumer, J. B., & Hepler, J. R. (2015). Protein-protein interactions: Methods 
and applications: Second edition. Methods Mol Biol, 1278, 1-457–465. 
https://doi.org/10.1007/978-1-4939-2425-7 
Burris, K. D., Pacheco, M. A., Filtz, T. M., Kung, M. P., Kung, H. F., & Molinoff, P. B. 
(1995). Lack of discrimination by agonists for d2 and d3 dopamine receptors. 
Neuropsychopharmacology, 12(4), 335–345. https://doi.org/10.1016/0893-
133X(94)00099-L 
Bylund, D. B., & Toews, M. L. (2011). Radioligand binding methods for membrane 
preparations and intact cells. Methods in Molecular Biology, 746, 135–164. 
https://doi.org/10.1007/978-1-61779-126-0_8 
Cheng, Y.-C., & Prusoff, W. H. (1973). Relationship between the inhibition constant (KI) 
and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an 
enzymatic reaction. Biochemical Pharmacology, 22(23), 3099–3108. 
https://doi.org/10.1016/0006-2952(73)90196-2 
Chien, E. Y. T., Liu, W., Zhao, Q., Katritch, V., Han, G. W., Hanson, M. A., Shi, L., 
Newman, A. H., Javitch, J. A., Cherezov, V., & Stevens, R. C. (2010). Structure of the 
human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science, 
330(6007), 1091–1095. https://doi.org/10.1126/science.1197410 
Chumpradit, S., Kung, M. P., Vessotskie, J., Foulon, C., Mu, M., & Kung, H. F. (1994). 
Iodinated 2-Aminotetralins and 3-Amino-1-benzopyrans: Ligands for Dopamine D2 
and D3 Receptors. Journal of Medicinal Chemistry, 37(24), 4245–4250. 
https://doi.org/10.1021/jm00050a021 
Dale, N. C., Johnstone, E. K. M., White, C. W., & Pfleger, K. D. G. (2019). NanoBRET: 
The bright future of proximity-based assays. Frontiers in Bioengineering and 
Biotechnology, 7(MAR), 1–13. https://doi.org/10.3389/fbioe.2019.00056 
De Lean, A., Stadel, J. M., & Lefkowitz, R. J. (1980). A ternary complex model explains the 
agonist-specific binding properties of the adenylate cyclase-coupled β-adrenergic 




Di Chiara, G., & Bassareo, V. (2007). Reward system and addiction: what dopamine does 
and doesn’t do. Current Opinion in Pharmacology, 7(1), 69–76. 
https://doi.org/10.1016/j.coph.2006.11.003 
Farooqui, T., & Farooqui, A. A. (2016). Perspective and Directions for Future Research on 
Trace Amines and Neurological Disorders. In Trace Amines and Neurological 
Disorders: Potential Mechanisms and Risk Factors. Elsevier Inc. 
https://doi.org/10.1016/B978-0-12-803603-7.00025-2 
Ferguson, S. S. G., Ill, W. E. D., Colapietro, A., Barak, L. S., Menard, L., & Caron, M. G. 
(1996). Role of P-Arrestin in Mediating Agonist-Promoted G Protein-Coupled 
Receptor Internalization. Science, 271, 3–6. 
Flanagan, C. A. (2016). GPCR-radioligand binding assays. Biophysical Methods in Cell 
Biology, 132, 191–215. https://doi.org/10.1016/bs.mcb.2015.11.004 
François Sautel, Nathalie Griffon, Daniel Lévesque, Catherine Pilon, Jean-Charles 
Schwartz, P. S. (1995). A functional test identifies dopamine agonists selective for D3 
versus D2 receptors. NeuroReport, 6(2), 329–332. 
Freedman, S. B., Patel, S., Marwood, R., Emms, F., Seabrook, G. R., Knowles, M. R., & 
McAllister, G. (1994). Expression and pharmacological characterization of the human 
D3 dopamine receptor. Journal of Pharmacology and Experimental Therapeutics, 
268(1), 417–426. 
Fu, J., Lee, T., & Qi, X. (2014). The identification of high-affinity G protein-coupled 
receptor ligands from large combinatorial libraries using multicolor quantum dot-
labeled cell-based screening. Future Med Chem, 6(7), 809–823. 
https://doi.org/10.4155/fmc.14.38.The 
Gainetdinov, R. R., Premont, R. T., Bohn, L. M., Lefkowitz, R. J., & Caron, M. G. (2004). 
Desensitization of G protein-coupled receptors and neuronal functions. Annual Review 
of Neuroscience, 27, 107–144. 
https://doi.org/10.1146/annurev.neuro.27.070203.144206 
Gether, U. (2000). Uncovering molecular mechanisms involved in activation of G protein-
coupled receptors. Endocrine Reviews, 21(1), 90–113. 
https://doi.org/10.1210/edrv.21.1.0390 
Gijsbers, A., Nishigaki, T., & Sánchez-puig, N. (2016). Fluorescence Anisotropy as a Tool 
to Study Protein-protein Interactions. Journal of Visualized Experiments, October, 1–
9. https://doi.org/10.3791/54640 
Gingrich, J. A., & Caron, M. G. (1993). Recent advances in the molecular biology of 
dopamine receptors. Annual Review of Neuroscience, 16, 299–231. 
https://doi.org/10.1146/annurev.ne.16.030193.001503 
Grätz, L., Tropmann, K., Bresinsky, M., Müller, C., Bernhardt, G., & Pockes, S. (2020). 
NanoBRET binding assay for histamine H2 receptor ligands using live recombinant 
HEK293T cells. Scientific Reports, 10(1), 1–10. https://doi.org/10.1038/s41598-020-
70332-3 
Hall, H., Farde, L., & Sedvall, G. (1988). Neural Transmission Human dopamine receptor 
subtypesmin vitro binding analysis using. Journal of Neural Transmission, 73, 7–21. 
Harris, A., Cox, S., Burns, D., & Norey, C. (2003). Miniaturization of Fluorescence 




Hausdorff, W. P., Caron, M. G., & Lefkowitz, R. J. (1990). Turning off the signal: 
desensitization of β‐adrenergic receptor function. Federation of American Societies for 
Experimental Biology, 4(11), 2881–2889. 
Hern, J. A., Baig, A. H., Mashanov, G. I., Birdsall, B., Corrie, J. E. T., & Lazareno, S. (2010). 
Formation and dissociation of M 1 muscarinic receptor dimers seen by total internal re 
flection fluorescence imaging of single molecules. Proc Natl Acad Sci U S A., 107(6), 
1–6. https://doi.org/10.1073/pnas.0907915107 
Hoare, B. L., Bruell, S., Sethi, A., Gooley, P. R., Lew, M. J., Hossain, M. A., Inoue, A., 
Scott, D. J., & Bathgate, R. A. D. (2019). Multi-Component Mechanism of H2 Relaxin 
Binding to RXFP1 through NanoBRET Kinetic Analysis. CellPress, 11, 93–113. 
https://doi.org/10.1016/j.isci.2018.12.004 
Hughes, L. D., Rawle, R. J., Boxer, S. G., Alexa, C., Alexa, C., Alexa, C., Alexa, C., Bodipy-
tmr, C., Invitrogen, P., Nhs-ester, O. R. A., Nhs-ester, A., Se, A., Alexa, M., Alexa, M., 
& Se, A. (2014). Choose Your Label Wisely : Water-Soluble Fluorophores Often 
Interact with Lipid Bilayers. 9(2). https://doi.org/10.1371/journal.pone.0087649 
Hulme, E. C., & Trevethick, M. A. (2010). Ligand binding assays at equilibrium: Validation 
and interpretation. British Journal of Pharmacology, 161(6), 1219–1237. 
https://doi.org/10.1111/j.1476-5381.2009.00604.x 
Iversen, S. D., & Iversen, L. L. (2007). Dopamine: 50 years in perspective. Trends in 
Neurosciences, 30(5), 188–193. https://doi.org/10.1016/j.tins.2007.03.002 
Jackson, T. (1991). Structure and function of G protein coupled receptors. Pharmacology 
and Therapeutics, 50(3), 425–442. https://doi.org/10.1016/0163-7258(91)90052-N 
Jacob, C., & Bunnett, N. W. (2006). Transmembrane Signaling by G Protein-Coupled 
Receptors. In Physiology of the Gastrointestinal Tract (Fourth Edi, pp. 63–90). Elsevier 
Inc. https://doi.org/10.1016/B978-0-12-088394-3.50006-4 
Jameson, D. M., & Ross, J. A. (2011). Fluorescence Polarization/Anisotropy in Diagnostics 
and Imaging. Chem Rev, 110(5), 2685–2708. 
https://doi.org/10.1021/cr900267p.Fluorescence 
Jong, L. A. A. De, Uges, D. R. A., Piet, J., & Bischoff, R. (2005). Receptor – ligand binding 
assays : Technologies and Applications. Journal of Chromatography B, 829, 1–25. 
https://doi.org/10.1016/j.jchromb.2005.10.002 
Joyce, J., & Millan, M. (2005). Dopamine D 3 receptor antagonists as therapeutic agents. 
Drug Discovery Today, 10(13). 
http://www.sciencedirect.com/science/article/pii/S1359644605034914 
Kasai, R. S., Ito, S. V, Awane, R. M., Fujiwara, T. K., & Kusumi, A. (2018). The Class-A 
GPCR Dopamine D2 Receptor Forms Transient Dimers Stabilized by Agonists : 
Detection by Single-Molecule Tracking. Cell Biochemistry and Biophysics, 29–37. 
https://doi.org/10.1007/s12013-017-0829-y 
Kelly, E., Bailey, C. P., & Henderson, G. (2008). Agonist-selective mechanisms of GPCR 
desensitization. British Journal of Pharmacology, 153, 379–388. 
https://doi.org/10.1038/sj.bjp.0707604 
Kim, K., Valenzano, K. J., Robinson, S. R., Yao, W. D., Barak, L. S., & Caron, M. G. (2001). 
Differential Regulation of the Dopamine D 2 and D 3 Receptors by G Protein-coupled 




Kobilka, B. K. (2007). G protein coupled receptor structure and activation. Biochimica et 
Biophysica Acta - Biomembranes, 1768(4), 794–807. 
Koob, G. F., & Volkow, N. D. (2010). Neurocircuitry of addiction. 
Neuropsychopharmacology, 35(1), 217–238. https://doi.org/10.1038/npp.2009.110 
Krupnick, J. G., & Benovic, J. L. (1998). THE ROLE OF RECEPTOR KINASES AND 
ARRESTINS IN G PROTEIN – COUPLED RECEPTOR REGULATION. Annual 
Review of Pharmacology and Toxicology, 38(1), 289–319. 
Laasfeld, T., Ehrminger, R., Tahk, M. J., Veiksina, S., Kõlvart, K. R., Min, M., Kopanchuk, 
S., & Rinken, A. (2021). Budded baculoviruses as a receptor display system to quantify 
ligand binding with TIRF microscopy. Nanoscale, 13(4), 2436–2447. 
https://doi.org/10.1039/d0nr06737g 
Lakowicz, J. R. (2006). Fluorescence Anisotropy. In Principles of Fluorescence 
Spectroscopy (pp. 353–382). https://doi.org/10.1007/978-0-387-46312-4_10 
Le Foll, B., Wilson, A. A., Graff, A., Boileau, I., & Di Ciano, P. (2014). Recent methods for 
measuring dopamine D3 receptor occupancy in vivo: Importance for drug development. 
Frontiers in Pharmacology, 5 JUL(July), 1–12. 
https://doi.org/10.3389/fphar.2014.00161 
Lea, W. A., & Simeonov, A. (2011). Fluorescence polarization assays in small molecule 
screening. Expert Opinion on Drug Discovery, 6(1), 17–32. 
https://doi.org/10.1517/17460441.2011.537322 
Li, Z. S., Schmauss, C., Cuenca, A., Ratcliffe, E., & Gershon, M. D. (2006). Physiological 
modulation of intestinal motility by enteric dopaminergic neurons and the D2 receptor: 
Analysis of dopamine receptor expression, location, development, and function in wild-
type and knock-out mice. Journal of Neuroscience, 26(10), 2798–2807. 
https://doi.org/10.1523/JNEUROSCI.4720-05.2006 
Li, Z., Zhou, X., & Dai, Z. (2012). Classification of G proteins and prediction of GPCRs-G 
proteins coupling specificity using continuous wavelet transform and information 
theory. Amino Acids, 43(2), 793–804. https://doi.org/10.1007/s00726-011-1133-6 
Luckow, V. A. (1993). Baculovirus systems for the expression of human gene products. 
Current Opinion in Biotechnology, 564–572. 
Luttrell, L M, Ferguson, S. S. ., Y.Daaka, Miller, W. ., S.Maudsley, Rocca, G. . Della, F.-
T.Lin, H.Kawakatsu, K.Owada, D.K.Luttrell, Caron, M. ., & Lefkowitz, R. . (1999). 
Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase 
complexes. Science, 283, 655–661. 
Luttrell, Louis M. (2006). Transmembrane Signaling by G Protein-Coupled Receptors. In 
Methods in Molecular Biolody (Vol. 332, pp. 3–49). 
MacKenzie, R. G., VanLeeuwen, D., Pugsley, T. A., Shih, Y. H., Demattos, S., Tang, L., 
Todd, R. D., & O’Malley, K. L. (1994). Characterization of the human dopamine D3 
receptor expressed in transfected cell lines. European Journal of Pharmacology: 
Molecular Pharmacology, 266(1), 79–85. https://doi.org/10.1016/0922-
4106(94)90212-7 
Martel, J. C., & McArthur, S. G. (2020). Dopamine Receptor Subtypes , Physiology and 
Pharmacology : New Ligands and Concepts in Schizophrenia. Frontiers in 
Neuroscience, 11, 1–17. https://doi.org/10.3389/fphar.2020.01003 
Massotte, D. (2003). G protein-coupled receptor overexpression with the baculovirus-insect 
44 
 
cell system: A tool for structural and functional studies. Biochimica et Biophysica Acta 
- Biomembranes, 1610(1), 77–89. https://doi.org/10.1016/S0005-2736(02)00720-4 
McKinney, M., & Raddatz, R. (2006). Practical aspects of radioligand binding. Current 
Protocols in Pharmacology / Editorial Board, S.J. Enna (Editor-in-Chief) ... [et Al.], 
Chapter 1(1), 1–42. https://doi.org/10.1002/0471141755.ph0103s33 
Meiser, J., Weindl, D., & Hiller, K. (2013). Complexity of dopamine metabolism. Cell 
Communication and Signaling, 11(1), 1–18. https://doi.org/10.1186/1478-811X-11-34 
Mierau, J., Schneider, F. J., Ensinger, H. A., Chio, C. L., Lajiness, M. E., & Huff, R. M. 
(1995). Pramipexole binding and activation of cloned and expressed dopamine D2, D3 
and D4 receptors. European Journal of Pharmacology: Molecular Pharmacology, 
290(1), 29–36. https://doi.org/10.1016/0922-4106(95)90013-6 
Millan, M. J., Maiofiss, L., Cussac, D., Audinot, V., Boutin, J. A., & Newman-Tancredi, A. 
(2002). Differential actions of antiparkinson agents at multiple classes of 
monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs 
at 21 native and cloned human receptor subtypes. Journal of Pharmacology and 
Experimental Therapeutics, 303(2), 791–804. https://doi.org/10.1124/jpet.102.039867 
Millan, M. J., Vian, J., Gobert, A., & Bervoets, K. (1995). D3 Receptor Activation in the 
Rat In Vivo and Their Modulation and Catalepsy. The Journal of Pharmacology and 
Experimental Therapeutics, 275(2), 885–898. 
Mishra, A., Singh, S., & Shukla, S. (2018). Physiological and Functional Basis of Dopamine 
Receptors and Their Role in Neurogenesis: Possible Implication for Parkinson’s 
disease. Journal of Experimental Neuroscience, 12. 
https://doi.org/10.1177/1179069518779829 
Missale, C., Russel Nash, S., Robinson, S. W., Jaber, M., & Caron, M. G. (1998). Dopamine 
receptors: From structure to function. Physiological Reviews, 78(1), 189–225. 
https://doi.org/10.1152/physrev.1998.78.1.189 
National Center for Biotechnology Information (2021). PubChem Compound Summary for 
CID 681, Dopamine. Retrieved May 6, 2021 
from https://pubchem.ncbi.nlm.nih.gov/compound/Dopamine 
 
Nelson, D. L., & Cox, M. M. (2017). Biosignaling. In Lehninger Principles of Biochemistry 
(7th ed., pp. 1129–1264). 
Neubig, R. R., Spedding, M., Kenakin, T., & Christopoulos, A. (2003). International Union 
of Pharmacology Committee on Receptor Nomenclature and Drug Classification . 
XXXVIII . Update on Terms and Symbols in Quantitative Pharmacology. Pharma, 
55(4), 597–606. https://doi.org/10.1124/pr.55.4.4.and 
Newton, P., Harrison, P., & Clulow, S. (2008). A Novel Method for Determination of the 
Affinity of Protein : Protein Interactions in Homogeneous Assays. Journal of 
Biomolecular Screening, 137(7), 674–682. https://doi.org/10.1177/1087057108321086 
Paton, W. D. M., & Rang, H. P. (1965). The Uptake of Atropine and Related Drugs by 
Intestinal Smooth Muscle of the Guinea-Pig in Relation to Acetylcholine Receptors. 
Proc R Soc Lond B Biol Sci., 163. https://doi.org/10.1098/rspb.1965.0058 
Patsenker, L. D., Tatarets, A. L., Povrozin, Y. A., & Terpetschnig, E. A. (2011). Long-




Pierce, K. L., & Lefkowitz, R. J. (2001). β -ARRESTINS IN THE REGULATION OF G-
PROTEIN-COUPLED RECEPTORS. Nat Rev Neurosci, 2(10), 727–733. 
Pierre, S., Bruno, G., Marie-Pascale, M., Marie-Louise, B., & Jean-Charles, S. (1990). 
Molecular Cloning and characterization of a novel dopamine receptor (D3) as a target 
for neuroleptics. Nature, 347. 
Pitcher, J. A., Freedman, N. J., & Lefkowitz, R. J. (1998). G PROTEIN – COUPLED 
RECEPTOR KINASES. Annual Review of Biochemistry, 67, 653–692. 
Prieto, G. A. (2017). Abnormalities of Dopamine D 3 Receptor Signaling in the Diseased 
Brain. Journal of Central Nervous System Disease, 9, 1–8. 
https://doi.org/10.1177/1179573517726335 
Pugsley, T. A., Davis, M. D., Akunne, H. C., Mackenzie, R. G., Shih, Y. H., Damsma, G., 
Wikstrom, H., Whetzel, S. Z., Georgic, L. M., Cooke, L. W., Demattos, S. B., Corbin, 
A. E., Glase, S. A., Wise, L. D., Dijkstra, D., & Heffner, T. G. (1995). Neurochemical 
and functional characterization of the preferentially selective dopamine D3 agonist PD 
128907. Journal of Pharmacology and Experimental Therapeutics, 275(3), 1355–1366. 
Rajagopal, S., & Shenoy, S. K. (2018). GPCR desensitization: Acute and Prolonged Phases. 
Cellular Signaling, 41, 9–16. https://doi.org/10.1016/j.cellsig.2017.01.024.GPCR 
Rinken, A., Lavogina, D., & Kopanchuk, S. (2018). Assays with Detection of Fluorescence 
Anisotropy : Challenges and Possibilities for Characterizing Ligand Binding to GPCRs. 
Trends in Pharmacological Sciences, 1–13. https://doi.org/10.1016/j.tips.2017.10.004 
Román, V., Gyertyán, I., Sághy, K., Kiss, B., & Szombathelyi, Z. (2013). Cariprazine (RGH-
188), a D3-preferring dopamine D 3/D2 receptor partial agonist antipsychotic candidate 
demonstrates anti-abuse potential in rats. Psychopharmacology, 226(2), 285–293. 
https://doi.org/10.1007/s00213-012-2906-7 
Rondou, P., Haegeman, G., & Van Craenenbroeck, K. (2010). The dopamine D4 receptor: 
biochemical and signalling properties. Cellular and Molecular Life Sciences : CMLS, 
67(12), 1971–1986. https://doi.org/10.1007/s00018-010-0293-y 
Rosenbaum, D., Rasmussen, S., & Brian, K. (2014). The structure and function of G protein 
coupled receptors. Nature, 459(7245), 356–363. 
https://doi.org/10.1038/nature08144.The 
Saarenpää, T., Jaakola, V., & Goldman, A. (2015). Baculovirus-Mediated Expression of 
GPCRs in Insect Cells. In Methods in Enzymology (pp. 185–218). 
https://doi.org/10.1016/bs.mie.2014.12.033 
Sabirsh, A., Wetterholm, A., Bristulf, J., Leffler, H., Haeggström, J. Z., & Owman, C. 
(2005). Fluorescent leukotriene B 4 : potential applications. Journal of Lipid Research, 
46, 1339–1346. https://doi.org/10.1194/jlr.D500005-JLR200 
Sakyiamah, M. M., Nomura, W., Kobayakawa, T., & Tamamura, H. (2019). Development 
of a NanoBRET-based sensitive screening method for CXCR4 ligands. Bioconjugate 
Chemistry, 30(5), 1442–1450. https://doi.org/10.1021/acs.bioconjchem.9b00182 
Schmidt, H., & Jirstrand, M. (2006). Systems Biology Toolbox for MATLAB : a 
computational platform for research in systems biology. Bioinformatics, 22(4), 514–
515. https://doi.org/10.1093/bioinformatics/bti799 
Schmieg, N., Rocchi, C., Romeo, S., Maggio, R., Millan, M. J., & Mannoury La Cour, C. 
(2016). Dysbindin-1 modifies signaling and cellular localization of recombinant, 




Schneider, E. H., & Seifert, R. (2010). Sf9 cells: A versatile model system to investigate the 
pharmacological properties of G protein-coupled receptors. Pharmacology and 
Therapeutics, 128(3), 387–418. https://doi.org/10.1016/j.pharmthera.2010.07.005 
Schnurr, B., Ahrens, T., & Regenass, U. (2006). Optical assays in drug discovery. In 
Comprehensive Medicinal Chemistry II (Vol. 3, pp. 577–598). 
https://doi.org/10.1016/b0-08-045044-x/00100-0 
Shenoy, S. K., & Lefkowitz, R. J. (2003). Multifaceted roles of β -arrestins in the regulation 
of seven-membrane- spanning receptor trafficking and signalling. Biochemical Journal, 
375, 503–515. 
Shenoy, S. K., & Lefkowitz, R. J. (2005). Seven-Transmembrane Receptor Signaling 
Through β -Arrestin. Science Signalling, 308. 
https://doi.org/10.1126/stke.2005/308/cm10 
Shepherd, T. R., & Fuentes, E. J. (2011). Structural and Thermodynamic Analysis of PDZ – 
Ligand Interactions. In Methods in Enzymology (Vol. 488, pp. 81–100). 
https://doi.org/10.1016/B978-0-12-381268-1.00004-5 
Silverdale, M. A., Nicholson, S. L., Ravenscroft, P., Crossman, A. R., Millan, M. J., & 
Brotchie, J. M. (2004). Selective blockade of D 3 dopamine receptors enhances the anti- 
parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate. 
Experimental Neurobiology, 188, 128–138. 
https://doi.org/10.1016/j.expneurol.2004.03.022 
Soave, M., Briddon, S. J., Hill, S. J., & Stoddart, L. A. (2020). Fluorescent ligands: Bringing 
light to emerging GPCR paradigms. British Journal of Pharmacology, 177(5), 978–
991. https://doi.org/10.1111/bph.14953 
Sokoloff, P., Diaz, J., Foll, B., Guillin, O., Leriche, L., Bezard, E., & Gross, C. (2006). The 
Dopamine D3 Receptor: A Therapeutic Target for the Treatment of Neuropsychiatric 
Disorders. CNS & Neurological Disorders - Drug Targets, 5(1), 25–43. 
https://doi.org/10.2174/187152706784111551 
Sokoloff, Pierre, Andrieux, M., Besançon, R., Pilon, C., Martres, M. P., Giros, B., & 
Schwartz, J. C. (1992). Pharmacology of human dopamine D3 receptor expressed in a 
mammalian cell line: comparison with D2 receptor. European Journal of 
Pharmacology: Molecular Pharmacology, 225(4), 331–337. 
https://doi.org/10.1016/0922-4106(92)90107-7 
Sokoloff, Pierre, Giros, B., Martres, M. P., Bouthenet, M. L., & Schwartz, J. C. (1990). 
Molecular cloning and characterization of a novel dopamine receptor (D3) as a target 
for neuroleptics. Nature, 347(6289), 146–151. https://doi.org/10.1038/347146a0 
Stoddart, L. A., Johnstone, E. K. M., Wheal, A. J., Goulding, J., Robers, M. B., Machleidt, 
T., Wood, K. V, Hill, S. J., & Pfleger, K. D. G. (2015). Application of BRET to monitor 
ligand binding to GPCRs Europe PMC Funders Group. Nat Methods, 12(7), 661–663. 
https://doi.org/10.1038/nmeth.3398.Application 
Stoddart, L. A., Kilpatrick, L. E., Briddon, S. J., & Hill, S. J. (2015). Probing the 
pharmacology of G protein-coupled receptors with fluorescent ligands. 
Neuropharmacology, 98, 48–57. https://doi.org/10.1016/j.neuropharm.2015.04.033 
Sun, N., Zhang, X., Guo, S., Le, H. T., Zhang, X., & Kim, K. M. (2018). Molecular 
mechanisms involved in epidermal growth factor receptor-mediated inhibition of 
47 
 
dopamine D3 receptor signaling. Biochimica et Biophysica Acta - Molecular Cell 
Research, 1865(9), 1187–1200. https://doi.org/10.1016/j.bbamcr.2018.06.001 
Svennilson, J., & Aperia, A. (2000). Dopamine in the developing kidney. International 
Journal of Developmental Biology, 43(5), 441–443. 
https://doi.org/10.1387/ijdb.10535321 
Tabor, A., Möller, D., Hübner, H., Kornhuber, J., & Gmeiner, P. (2017). Visualization of 
ligand-induced dopamine D2S and D2L receptor internalization by TIRF microscopy. 
Scientific Reports, 7(1), 1–11. https://doi.org/10.1038/s41598-017-11436-1 
Tang, L., Todd, R. D., Heller, A., & O’Malley, K. L. (1994). Pharmacological and functional 
characterization of D2, D3 and D4 dopamine receptors in fibroblast and dopaminergic 
cell lines. Journal of Pharmacology and Experimental Therapeutics, 268(1), 495–502. 
Tuteja, N. (2009). Signaling through G protein coupled receptors. Plant Signaling and 
Behavior, 4(10), 942–947. https://doi.org/10.4161/psb.4.10.9530 
Vallone, D., Picetti, R., & Borrelli, E. (2000). Structure and function of dopamine receptors. 
Neuroscience and Behavioural Reviews, 24(99), 125–132. 
Van Tol, H. H. M., Bunzow, J. R., Guan, H. C., Sunahara, R. K., Seeman, P., Niznik, H. B., 
& Civelli, O. (1991). Cloning of the gene for a human dopamine D4 receptor with high 
affinity for the antipsychotic clozapine. Nature, 350(6319), 610–614. 
https://doi.org/10.1038/350610a0 
Veiksina, S., Kopanchuk, S., & Rinken, A. (2014). Biochimica et Biophysica Acta Budded 
baculoviruses as a tool for a homogeneous fl uorescence anisotropy-based assay of 
ligand binding to G protein-coupled receptors : The case of melanocortin 4 receptors. 
BBA - Biomembranes, 1838(1), 372–381. 
https://doi.org/10.1016/j.bbamem.2013.09.015 
Villar, V. A. M., Jones, J. E., Armando, I., Palmes-Saloma, C., Yu, P., Pascua, A. M., 
Keever, L., Arnaldo, F. B., Wang, Z., Luo, Y., Felder, R. A., & Jose, P. A. (2009). G 
protein-coupled receptor kinase 4 (GRK4) regulates the phosphorylation and function 
of the dopamine D3 receptor. Journal of Biological Chemistry, 284(32), 21425–21434. 
https://doi.org/10.1074/jbc.M109.003665 
Wang, Q., Bosch, B., Vlak, J. M., Oers, M. M. Van, Rottier, P. J., & Lent, J. W. M. Van. 
(2016). Budded baculovirus particle structure revisited. Journal of Invertebrate 
Pathology, 134, 15–22. https://doi.org/10.1016/j.jip.2015.12.001 
Witkovsky, P. (2004). Dopamine and retinal function. Documenta Ophthalmologica, 108(1), 
17–39. https://doi.org/10.1023/B:DOOP.0000019487.88486.0a 
Xi, Z., & Gardner, E. L. (2007). Pharmacological Actions of NGB 2904 , a Selective 
Dopamine D 3 Receptor Antagonist , in Animal Models of Drug Addiction. CNS Drug 
Reviews, 13(2), 240–259. 
Yakimchuk 2011 
Konstantin Yakimchuk  
MATER METHODS 2011;1:199 
Yuan, J., Chen, X., Brodbeck, R., Primus, R., Braun, J., Wasley, J. W. F., & Thurkauf, A. 
(1998). NGB 2904 AND NGB 2849 : TWO HIGHLY SELECTIVE DOPAMINE D3 






















Figure 1. TFI change in time caused by binding of A2-TAMRA to D3R displayed on 
BBV. Nonspecific binding was determined with 316 µM 7-hydroxyDPAT hydrobromide. Total 
binding was determined in the absence of 7-hydroxyDPAT hydrobromide. Data shown is from a 















Table 1. pKi values of D3R ligands determined in competition binding experiments 
between D3R ligands and A2-TAMRA and [
3H]-methylspiperone. Serial dilutions of 
competitor ligands were incubated with fixed concentrations of BBV and A2-TAMRA for 
FA assay or [3H]-methylspiperone for radioligand binding assay. Data shows mean ± S.E.M of 
at least three independent experiments done in duplicates (for FA experiments) or triplicates (for 
radioligand binding assay). 
 
 













Antagonists    
Sulpiride 6.6 ± 0.1 7.6 ± 0.4 7.3 ± 0.5 
Butaclamol 7.5 ± 0.2  8.5 ± 0.3 
Spiperone 8.3 ± 0.1 9.2 ± 0.4 9.2 ± 0.1 
Raclopride 7.6 ± 0.2 8.8 ± 0.5 8.9 ± 0.2 
Agonists    
Quinpirole (full agonist) 5.3 ± 0.2 6.2 ± 0.2 8.1 ± 0.3 
Dopamine (full agonist) 5.4 ± 0.1  7.7 ± 0.2 
7-hydroxypipat maleate (full ag-
onist) 
8.2 ± 0.1  7.5 ± 2.1 
7-hydroxy DPAT hydrobromide 7.2 ± 0.1  8.8 ± 0.2 
Terguride (partial agonist 8.1 ± 0.1  9.0 ± 0.1 
















































Figure 2. Correlation plots of pKi from FA assay and pKi from literature. (A) Correlation 
between FA-obtained pKi and pKi values from literature for the ten D3R ligands. Solid line shows 
linear regression, dashed lines represent 95 % confidence intervals, vertical error bars show 
uncertainty limits for FA-obtained pKi values and horizontal bars show uncertainty limits for 
literature pKi values. (B) Correlation between FA-obtained pKi values and literature pKi  values 





R2 = 0.88 





















































Figure 3. Correlations between pKi values obtained from radioligand binding assay 
and pKi values from literature. (A) Correlation between pKi values obtained from radioligand 
binding assay and literature pKi for the antagonists sulpiride, raclopride, spiperone, the partial agonist 
apomorphine, and the full agonist quinpirole. Solid line shows linear regression, dashed lines 
represent 95 % confidence intervals; vertical error bars show uncertainty limits for pKi values 
determined in radioligand binding assay and horizontal error bars show uncertainty limits for pKi 
values from literature. (B) Correlation between pKi values from radioligand binding assay and 
literature pKi except for the full agonist quinpirole.  
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